Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Working Capital Changes (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Other Working Capital Changes for 7 consecutive years, with -$6.7 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 69.84% to -$6.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$11.4 million through Dec 2025, down 641.12% year-over-year, with the annual reading at -$11.4 million for FY2025, 641.12% down from the prior year.
  • Other Working Capital Changes hit -$6.7 million in Q4 2025 for BridgeBio Pharma, down from $1.7 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $25.7 million in Q3 2022 to a low of -$22.1 million in Q4 2024.
  • Historically, Other Working Capital Changes has averaged $779473.7 across 5 years, with a median of -$1.4 million in 2021.
  • Biggest five-year swings in Other Working Capital Changes: plummeted 18206.25% in 2022 and later skyrocketed 631.5% in 2024.
  • Year by year, Other Working Capital Changes stood at $6.1 million in 2021, then tumbled by 128.11% to -$1.7 million in 2022, then surged by 519.8% to $7.2 million in 2023, then plummeted by 408.64% to -$22.1 million in 2024, then skyrocketed by 69.84% to -$6.7 million in 2025.
  • Business Quant data shows Other Working Capital Changes for BBIO at -$6.7 million in Q4 2025, $1.7 million in Q3 2025, and -$4.9 million in Q2 2025.